viveksubbiah.bsky.social - Profile | ThreadSky | a Reddit-style client for Bluesky

Check out Dr. @viveksubbiah.bsky.social's insights on managing #FGFR inhibitor side effects. Proactive monitoring is key to better outcomes in #urothelialcarcinoma and #cholangiocarcinoma: bit.ly/4129EXD Dr. Subbiah is also faculty at #GDST → www.hmpglobalevents.com/gdst #MedicalEducation #Cancer

submitted 17 days ago • 0 comments

The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials - Vivek Subbiah @viveksubbiah.bsky.social @weldeiry.bsky.social oncodaily.com/blog/vivek-s... #JCO #Oncology #OncoDaily #Cancer #Medicine #Health

submitted 28 days ago • 0 comments

A testament to the power of global collaboration in advancing healthcare - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/insight/vive... #Cancer #OncoDaily #Oncology #WorldCancerDay #Medicine #Health

submitted 29 days ago • 0 comments

Revolutionizing Cancer Therapy – Breaking Barriers in Oncology with Tumor-Agnostic Drug Development - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/blog/vivek-s... #Cancer #OncoDaily #Oncology #Medicine #Health

submitted 30 days ago • 0 comments

⭐️Evidence for a reduction in number of cycles of immune checkpoint inhibitors - The Lancet Oncology www.thelancet.com/journals/lan...

submitted 29 days ago • 0 comments

⭐️FDA approves new non-opioid pain drug. The FDA has approved Vertex’s suzetrigine (Journavx), an oral inhibitor of voltage-gated sodium channel 1.8 (NaV1.8), for the treatment of moderate to severe acute pain. www.nature.com/articles/d41...

submitted 30 days ago • 0 comments

5 articles suggested by Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/insight/vive... #Cancer #CancerResearch #Oncology #OncoDaily #Medicine #Health

submitted 34 days ago • 0 comments

🚨Hot of the press 👉🏼 Pleased to share our latest commentary in @natureportfolio.bsky.social NRCO 👉🏼 "Transforming Pediatric AML Trials: From Failing One-Size-Fits-All Methods to Precision Oncology” Thrilled to collaborate w the amazing Dr. Branko Cuglievan on this! www.nature.com/articles/s41...

submitted 34 days ago • 0 comments

🚨🥁🥁🥁Published online Live now on #FOXNEWS 👉🏼So excited to share the latest & greatest in cancer research in 2024 and what’s ahead in 2025 @foxnewscorporation.bsky.social Link : www.foxnews.com/health/year-...

submitted 70 days ago • 0 comments

Top Phase 1 clinical trial publications of 2024 - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/insight/217361 #OncoDaily #Oncology #Medicine #Health #Cancer #CancerResearch

submitted 56 days ago • 0 comments

Next-Generation Sequencing and Targets in Early-Phase Colorectal Cancer Drug Development @viveksubbiah.bsky.social oncodaily.com/dialogues/ne... #Cancer #GlobalCancerMovement #OncoDaily #Oncology #Medicine #Health

submitted 46 days ago • 0 comments

Oncologist Near Me – Vivek Subbiah: Pionner of Precision Oncology @viveksubbiah.bsky.social @scrinetwork.bsky.social @ishwaria.bsky.social oncodaily.com/oncolibrary/... #Cancer #OncoDaily #OncologistNearMe #Oncology #SCRI #Medicine #Health

submitted 46 days ago • 0 comments

🚨It’s Friday & we have another FDA approval 👉🏼FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors onclive.com/view/fda-appro… via https://www.onclive.com/view/fda-approves-subcutaneous-nivolumab-in-advanced-or-metastatic-solid-tumors

submitted 66 days ago • 0 comments

🚨One more paper to wrap up the amazing year for #PrecisionMedicine 👉🏼pleased to share our paper 👉🏼Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein pubs.acs.org/doi/10.1021/...

submitted 66 days ago • 0 comments

Artificial intelligence-aided data mining of medical records for cancer detection and screening @thelancet.bsky.social oncology www.thelancet.com/journals/lan...

submitted 67 days ago • 0 comments

⭐️Wishing everyone a Merry Christmas & Happy Holidays filled with joy, love, and laughter! #MerryChristmas #MerryChristmas2024

submitted 68 days ago • 1 comment

The year in cancer: Advances made in 2024, predictions for 2025 - insights from @viveksubbiah.bsky.social @erikahamilton9.bsky.social @krishpatelmd.bsky.social and Dr Meredith McKean from Sarah Cannon Cancer Institute www.foxnews.com/health/year-...

submitted 69 days ago • 0 comments

@viveksubbiah.bsky.social predicts “Within the next decade, I envision a landscape where precision oncology is seamlessly integrated into routine care.” - amen to that!! www.aacr.org/blog/2024/12...

submitted 69 days ago • 0 comments

Thrilled to Share My Latest Blog with AACR - Vivek Subbiah @viveksubbiah.bsky.social @theaacr.bsky.social oncodaily.com/blog/209360 #AACR #AACRBlog #Cancer #CancerResearch #OncoDaily #Oncology #PrecisionOncologyResearch #Medicine #Health

submitted 69 days ago • 0 comments

🚨🥁🥁🥁Published online Live now on #FOXNEWS 👉🏼So excited to share the latest & greatest in cancer research in 2024 and what’s ahead in 2025 @foxnewscorporation.bsky.social Link : www.foxnews.com/health/year-...

submitted 70 days ago • 0 comments

Some of us sat down with @foxnewscorporation.bsky.social to recap 2024 in cancer Ana make some predictions for the new year of 2025! @viveksubbiah.bsky.social @krishpatelmd.bsky.social www.foxnews.com/health/year-...

submitted 70 days ago • 0 comments

🌟 Thrilled to Share My Latest Blog with AACR - American Association of Cancer Research ⭐️Creating a World Where Precision Oncology is a Reality for All ⭐️2024 was a terrific year for precision oncology & looking forward for more advances in 2025 @theaacr.bsky.social www.aacr.org/blog/2024/12...

submitted 72 days ago • 0 comments

Leptomeningeal metastatic disease: new frontiers and future directions www.nature.com/articles/s41...

submitted 72 days ago • 0 comments

Rare & outstanding career opportunity #LegorretaCancerCenter @BrownUCancer @BrownMedicine @BrownPathology @BrownUnivHealth @BrownUniversity Physician-Investigator, Physician-Scientist or Scientist, Cancer Biology More info & application information: www.nature.com/naturecareer...

submitted 75 days ago • 0 comments

🩸🧬Exciting update! LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy addressing limits of imaging in solid tumors. A step toward precision oncology! @oncoalert.bsky.social @christianrolfo.bsky.social @viveksubbiah.bsky.social www.annalsofoncology.org/action/showP...

submitted 76 days ago • 1 comment

⭐️Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) - Annals of Oncology www.annalsofoncology.org/article/S092...

submitted 76 days ago • 0 comments

Early-onset colorectal cancer on the rise globally. 🚨Rates are increasing in 27/50 countries. 🚨🙋🏻‍♂️🙋‍♀️and younger adults face alarming trends. Awareness and early detection are critical! @oncoalert.bsky.social @realbowtiedoc.bsky.social @viveksubbiah.bsky.social www.thelancet.com/journals/lan...

submitted 77 days ago • 0 comments

⭐️Leptomeningeal metastatic disease: new frontiers and future directions @natureportfolio.bsky.social Nature Reviews Clinical Oncology www.nature.com/articles/s41...

submitted 77 days ago • 3 comments

ICYMI in Cancer Discovery: Zenocutuzumab, a #HER2 x #HER3 #Bispecific Antibody, Is Effective Therapy for Tumors Driven by #NRG1 Gene Rearrangements - by Alison Schram and colleagues @mskcancercenter.bsky.social doi.org/10.1158/2159...

submitted 88 days ago • 0 comments

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer – Day 1 oncodaily.com/blog/global-... @drjemm.bsky.social @viveksubbiah.bsky.social #OncoDaily #Oncology #CancerCare #Medicine #Health #SPCC #Cancer

submitted 84 days ago • 0 comments

🚨🚨🚨FDA approval alert 👉🏼FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma - for NRG fusions #PrecisionMedicine 🧬🎯 www.fda.gov/drugs/resour...

submitted 89 days ago • 0 comments

⭐️Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis www.thelancet.com/journals/lan...

submitted 90 days ago • 0 comments

Iincidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation Aimed to estimate the lifetime risk of #PancreaticCancer in women w/ BRCA1 & BRCA2 mutations. Annual risk of pancreatic cancer was 0.04% for BRCA1 & 0.09% for BRCA2 @realbowtiedoc.bsky.social @viveksubbiah.bsky.social

submitted 91 days ago • 1 comment

⭐️Artificial intelligence-aided data mining of medical records for cancer detection and screening www.thelancet.com/journals/lan...

submitted 90 days ago • 0 comments

go.bsky.app/4pWmu3W Share who you think should be added! 👇🏽👇🏽👇🏽👇🏽👇🏽

submitted 102 days ago • 3 comments

Impact of cycle 1 irAEs on ICI outcomes: - 683pts from SWOG DART trial - g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001 - g3+ irAEs = ⬇️OS HR 1.41 p= .025 - g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002 Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social academic.oup.com/jnci/advance...

submitted 94 days ago • 0 comments

Now I’m on @bsky.app #medtwitter peeps! @jrgralow.bsky.social @oncoalert.bsky.social @viveksubbiah.bsky.social @erictopol.bsky.social @subatomicdoc.bsky.social

submitted 94 days ago • 9 comments

The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial - Annals of Oncology www.annalsofoncology.org/article/S092...

submitted 94 days ago • 0 comments

⭐️Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Nice work spearheaded by @adesaimd.bsky.social mdpi.com/3031120

submitted 94 days ago • 0 comments

Friends, help us feed folks via #HCWvsHunger! Donate to any local food bank (find one https://buff.ly/2EhMZ28) or hunger org, 📸 your receipt, & log it for your fave #MedTwitter or #MedSky team at HCWvsHunger.org by 12/3. FAQs there too!

submitted 94 days ago • 0 comments

🍁Grateful hearts, joyful gatherings, and one filled with love and laughter. Wishing you all a blessed and bountiful Thanksgiving. 🍁🦃 #Thankful #Gratitude #HappyThanksgiving #thanksgiving2024 #Thanksgiving #Thanksgiving24 #oncsky #medsky

submitted 95 days ago • 0 comments

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer www.nejm.org/doi/full/10....

submitted 95 days ago • 0 comments

⭐️Nice review @theaacr.bsky.social journal Cancer Discovery 👉🏼The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development @ptarantinomd.bsky.social bit.ly/3YZn7OK

submitted 96 days ago • 1 comment

⭐️Development and phenotype of regulatory T cells This picture is worth 100 K words! Link to pdf: www.stemcell.com/media/files/...

submitted 98 days ago • 0 comments

🥁🥁🥁Super honored to host a JAMA Oncology podcast with the one & only giant of leukemia, Dr. Hagop Kantarjian 🎙️ Listen to a tour de force of all therapies in CML. ⭐️CML is the poster child for precision oncology Link: edhub.ama-assn.org/jn-learning/...

submitted 101 days ago • 0 comments

⭐️Pancreatic Cancer Surge May Be Less Worrisome Than It Seemed A rise in the disease in younger people was not followed by an increase in deaths, a study found, and might be a sign of overdiagnosis @nytimes.com www.nytimes.com/2024/11/18/h...

submitted 103 days ago • 0 comments

Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster -PD1xVEGF antibody ? www.statnews.com/2024/11/14/m...

submitted 104 days ago • 0 comments